Pioglitazone induces lipid accumulation in the rat heart despite concomitant reduction in plasma free fatty acid availability.
Thiazolidinediones are insulin-sensitizing drugs which have been proved to be effective in the treatment of type 2 diabetes. However, the action of thiazolidinediones on myocardial metabolism is only poorly recognized. Therefore, the aim of our study was to investigate the effects of two-week pioglitazone treatment (3 mg/kg/d) on lipid and carbohydrate metabolism in the heart of rats fed on a standard chow or on a high-fat diet (HFD) for three weeks. High-fat feeding increased myocardial protein expression of all peroxisome proliferator-activated receptor (PPAR) isoforms. The greatest response was, however, noted in the case of PPARgamma. Surprisingly, administration of pioglitazone induced accumulation of free fatty acids (FFA) and diacylglycerol in the heart in both groups, despite concomitant reduction in plasma FFA concentration. The content of triacylglycerol was increased only in the HFD group. Pioglitazone treatment also shifted myocardial substrate utilization towards greater contribution of glucose in both groups, as evidenced by decreased rate of palmitate oxidation and higher 2-deoxyglucose uptake and elevated glycogen content. This could induce a mismatch between the rate of myocardial fatty acid uptake and oxidation leading to increased intracellular availability of fatty acids for non-oxidative metabolic pathways like synthesis of acylglycerols. Our data suggests that thiazolidinediones improve cardiac insulin sensitivity by mechanisms other than reduction in intramyocardial lipid content.
Department of Physiology, Medical University of Bialystok, Mickiewicza 2c, 15-230 Bialystok, Poland. marcinb@amb.edu.pl
Marcin
M
Baranowski
Agnieszka
A
Blachnio-Zabielska
Piotr
P
Zabielski
Jan
J
Gorski
D000818:Animals; D003847:Deoxyglucose / Q000378:metabolism; D004041:Dietary Fats / Q000008:administration & dosage; D050556:Fatty Acid-Binding Proteins / Q000378:metabolism; D005230:Fatty Acids, Nonesterified / Q000097:blood*; D006003:Glycogen / Q000378:metabolism; D006321:Heart / Q000187:drug effects*; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D050356:Lipid Metabolism / Q000187:drug effects*; D008297:Male; D009206:Myocardium / Q000378:metabolism*; D010084:Oxidation-Reduction; D047492:Peroxisome Proliferator-Activated Receptors / Q000378:metabolism; D000077205:Pioglitazone; D051381:Rats; D017208:Rats, Wistar; D045162:Thiazolidinediones / Q000494:pharmacology*
D004041:Dietary Fats; D050556:Fatty Acid-Binding Proteins; D005230:Fatty Acids, Nonesterified; D007004:Hypoglycemic Agents; D047492:Peroxisome Proliferator-Activated Receptors; D045162:Thiazolidinediones; D006003:Glycogen; D003847:Deoxyglucose; D000077205:Pioglitazone